Geron Corporation targets the high end of its 2026 revenue guidance as it shifts commercial focus toward community-based treatment settings and earlier lines of therapy for MDS patients.
Revenue near high end of guidance, three straight growth quarters, expanding community use, and lowered operating expenses.
Geron Corporation expects 2026 RYTELO revenue to hit the high end of its $230 million to $240 million guidance. The company reports three consecutive quarters of growth and a 24% revenue increase in the first half, driven by deeper penetration into community treatment settings for lower-risk MDS patients.
Growth is fueled by three consecutive quarters of rising sales, a 24% revenue increase in the first half of the year, and a strategic pivot toward community treatment settings for lower-risk MDS patients.